In this week’s special Q&A episode, John Stanford tackles your biggest questions from around the biotech and policy world. From the growing list of drug price controls under the IRA to the newly announced 15% EU tariffs on medicines, there's a lot at stake for patients, companies, and innovation. John also breaks down the temporary NIH funding freeze, what it means for research, and why August recess matters more than you think.

What impact do you think drug price controls will have on innovation?
Should medicines be included in international tariff negotiations?
What policies should Congress prioritize this fall?

📱If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Timestamps:
0:00 Tech setup and behind-the-scenes
3:37 Welcome to the Making Medicine Podcast
4:16 Breaking news: FDA's SBER director steps down
4:58 Are we moving toward more price controls on drugs?
7:47 New EU trade deal and tariffs on pharmaceuticals
10:08 How the IRA continues to impact the investment environment
12:31 Did the White House freeze NIH funding?
15:10 What is August recess and why it matters
16:53 Final thoughts and call for listener questions